Back to top
more

Endocyte, Inc. (ECYT)

(Delayed Data from NSDQ)

$23.99 USD

23.99
NA

0.00 (0.00%)

Updated Dec 20, 2018 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Endocyte (ECYT) Up 0.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Endocyte (ECYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Endocyte (ECYT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Endocyte (ECYT) delivered earnings and revenue surprises of -6.25% and 330.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Endocyte (ECYT) Q3 Earnings Preview: What's Shaping Up?

by Zacks Equity Research

Endocyte (ECYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks.com featured highlights include: Lamb Weston, Dollar General, Endocyte and CONSOL

by Zacks Equity Research

Zacks.com featured highlights include: Lamb Weston, Dollar General, Endocyte and CONSOL

4 Stocks With Recent Price Strength to Strengthen Portfolio

by Zacks Equity Research

Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Top Ranked Momentum Stocks to Buy for October 25th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 25th:

Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT

by Zacks Equity Research

Three biotech stocks are scheduled to release their third-quarter results on Oct 24. Let's take a look at how these companies are poised ahead of their earnings release.

Novartis (NVS) Q3 Earnings In Line, Revenues Beat Estimates

by Zacks Equity Research

Novartis (NVS) beats sales estimates in Q3, driven by Cosentyx and Entresto, while earnings came in line. The company plans to acquire Endocyte to broaden its oncology pipeline.

Can The Uptrend Continue for Endocyte (ECYT)?

by Zacks Equity Research

Investors certainly have to be happy with Endocyte, Inc. (ECYT) and its short term performance.

Pharma/Biotech Stocks to Watch This Prostate Cancer Month

by Zacks Equity Research

Here we highlight a few companies that are focused on developing treatments for prostate cancer.

    Endocyte Announces FDA's Acceptance of Trial Endpoint Change

    by Zacks Equity Research

    177Lu-PSMA-617, a prostate specific membrane antigen-targeted radioligand therapy, is Endocyte's (ECYT) lead program. It is being evaluated in a phase III study for mCRPC for PSMA-positive patients

      Company News For Sep 11, 2018

      by Zacks Equity Research

      Companies in the news are: NKE, SAIC, EGL, BABA and ECYT

        Endocyte (ECYT) Soars: Stock Adds 11.4% in Session

        by Zacks Equity Research

        Endocyte (ECYT) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

          Is the Options Market Predicting a Spike in Endocyte (ECYT) Stock?

          by Zacks Equity Research

          Investors need to pay close attention to Endocyte (ECYT) stock based on the movements in the options market lately.

            Endocyte (ECYT) Up 14.6% Since Last Earnings Report: Can It Continue?

            by Zacks Equity Research

            Endocyte (ECYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Endocyte (ECYT) Posts Narrower-Than-Expected Loss in Q2

              by Zacks Equity Research

              Endocyte (ECYT) initiates a phase III VISION study for its lead pipeline candidate,-177Lu-PSMA-617, during the second quarter of 2018.

                Endocyte (ECYT) Posts Narrower than Expected Loss in Q2

                by Zacks Equity Research

                Endocyte (ECYT) posts narrower than expected Loss in the second quarter of 2018.

                  What's in Store for Intercept (ICPT) This Earnings Season?

                  by Zacks Equity Research

                  Investors will primarily focus on Ocaliva's performance along with other pipeline developments, when Intercept (ICPT) reports its Q2 results on Aug 2.

                    Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT

                    by Zacks Equity Research

                    Let's see how pharma/biotech stocks are poised ahead of their scheduled results on Jul 31.

                      Is a Beat in Store for Endocyte (ECYT) This Earnings Season?

                      by Zacks Equity Research

                      The investor's focus is expected to remain on updates from pipeline candidates 177Lu-PSMA-617, CAR-T cell program during the Q2 earnings call.

                        Has Endocyte (ECYT) Outpaced Other Medical Stocks This Year?

                        by Zacks Equity Research

                        Is (ECYT) Outperforming Other Medical Stocks This Year?

                          Endocyte (ECYT) Up 5.1% Since Earnings Report: Can It Continue?

                          by Zacks Equity Research

                          Endocyte (ECYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                            Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up

                            by Zacks Equity Research

                            Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.

                              Endocyte (ECYT) Posts Narrower than Expected Loss in Q1

                              by Zacks Equity Research

                              Endocyte???s first-quarter 2018 loss was narrower-than-expected.

                                What's in Store for Endocyte (ECYT) This Earnings Season?

                                by Zacks Equity Research

                                Endocyte (ECYT) is expected to provide updates on pipeline candidates when it reports first-quarter 2018 results on May 9 after the market closes.